Dev Prasad
Stock Analyst at Lucid Capital
(4.74)
# 660
Out of 4,690 analysts
17
Total ratings
75%
Success rate
88.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals | Initiated Coverage: Buy | $38 | $15.07 | +152.16% | 1 | Aug 20, 2026 | |
| PLYX Polaryx Therapeutics | Initiated Coverage: Buy | $7 | $2.06 | +239.81% | 1 | Jul 27, 2026 | |
| QNRX Quoin Pharmaceuticals | Initiated Coverage: Buy | $30 | $6.12 | +390.20% | 1 | May 4, 2026 | |
| ABOS Acumen Pharmaceuticals | Initiated Coverage: Buy | $6 | $2.92 | +105.48% | 1 | Dec 17, 2025 | |
| PVLA Palvella Therapeutics | Maintained: Buy | $49 → $212 | $149.97 | +41.36% | 2 | Dec 15, 2025 | |
| IFRX InflaRx | Maintained: Buy | $24 | $2.23 | +976.23% | 1 | Nov 10, 2025 | |
| VRCA Verrica Pharmaceuticals | Initiated Coverage: Buy | $19 | $5.69 | +233.92% | 1 | Nov 5, 2025 | |
| TSX: MDNA Medicenna Therapeutics Corp. | Initiated Coverage: Buy | $4.00 | $0.48 | +742.11% | 1 | Oct 14, 2025 | |
| ATYR aTyr Pharma | Downgraded: Hold | $1 | $0.54 | +85.19% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiated Coverage: Buy | $4 | $27.88 | n/a | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $3.69 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $4.62 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $6.91 | n/a | 1 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $1.36 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $19.59 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $0.4644 | n/a | 1 | Dec 17, 2024 |
Eloxx Pharmaceuticals
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $38
Current: $15.07
Upside: +152.16%
Polaryx Therapeutics
Jul 27, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.06
Upside: +239.81%
Quoin Pharmaceuticals
May 4, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $6.12
Upside: +390.20%
Acumen Pharmaceuticals
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $6
Current: $2.92
Upside: +105.48%
Palvella Therapeutics
Dec 15, 2025
Maintained: Buy
Price Target: $49 → $212
Current: $149.97
Upside: +41.36%
InflaRx
Nov 10, 2025
Maintained: Buy
Price Target: $24
Current: $2.23
Upside: +976.23%
Verrica Pharmaceuticals
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $5.69
Upside: +233.92%
Medicenna Therapeutics Corp.
Oct 14, 2025
Initiated Coverage: Buy
Price Target: $4.00
Current: $0.48
Upside: +742.11%
aTyr Pharma
Sep 15, 2025
Downgraded: Hold
Price Target: $1
Current: $0.54
Upside: +85.19%
Cue Biopharma
Aug 25, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $27.88
Upside: n/a
Jun 17, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $3.69
Upside: n/a
May 23, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $4.62
Upside: n/a
May 1, 2025
Initiated Coverage: Buy
Price Target: $36
Current: $6.91
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $6
Current: $1.36
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $24
Current: $19.59
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $13
Current: $0.4644
Upside: n/a